Xtant Medical Holdings ( (XTNT) ) has provided an announcement.
On April 15, 2025, Xtant Medical Holdings terminated its Investor Rights Agreement with ROS Acquisition and ORO II following a secondary private sale of 73.1 million shares by OrbiMed to Nantahala Capital Management and other investors. This transaction provides Xtant with greater strategic flexibility and aligns it with long-term healthcare-focused investors. Xtant plans to prioritize profitability and self-sustainability by shifting towards higher-margin orthobiologics and leveraging its Montana manufacturing facility. The company anticipates revenue growth of 18% to 19% for the first quarter of 2025, driven by orthobiologics and licensing revenue.
Spark’s Take on XTNT Stock
According to Spark, TipRanks’ AI Analyst, XTNT is a Neutral.
Xtant Medical Holdings’ overall stock score is primarily impacted by its ongoing financial struggles, including persistent losses and liquidity issues. While there is some optimism from projected revenue growth and cost-cutting strategies, the negative trend in technical analysis and weak valuation metrics underscore significant risks. Improvements in financial performance and successful execution of strategic initiatives will be crucial for future stock performance.
To see Spark’s full report on XTNT stock, click here.
More about Xtant Medical Holdings
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of orthobiologics and spinal implant systems. The company aims to facilitate spinal fusion in complex spine, deformity, and degenerative procedures, with a mission centered on enhancing patient lives through innovative surgical solutions.
YTD Price Performance: -17.02%
Average Trading Volume: 76,926
Technical Sentiment Signal: Buy
Current Market Cap: $55.63M
For an in-depth examination of XTNT stock, go to TipRanks’ Stock Analysis page.